Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram).

Therapeutic drug monitoring - 1 Feb 2006

Rudberg Ida, Hendset Magnhild, Uthus Linda Hårstad, Molden Espen, Refsum Helge

Abstract excerpt

There is limited documentation of the importance of heterozygous cytochrome P450 (CYP) mutations on drug exposure. This study was designed to evaluate the influence of heterozygous mutations in CYP2C19 on the serum concentration of racemic citalopram and escitalopram (S-citalopram). Eighty-three samples from subjects with determined CYP2C19 and CYP2D6 genotype receiving racemic citalopram or S-citalopram as part...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Citalopram

Share to Cytochrome P-450 CYP2C19

Share to Drug Monitoring

Share to Mixed Function Oxygenases

Share to Selective Serotonin Reuptake Inhibitors

Share to Stereoisomerism

Source

Identifiers

PMID: 16418702
DOI: 10.1097/01.ftd.0000189899.23931.76

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram).PMID 16418702Read ↗

Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis.Semantic proximity Read ↗

Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.Semantic proximity Read ↗

Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients.Semantic proximity Read ↗

Effects of CYP2C19 genetic polymorphism on the steady-state concentration of citalopram in patients with major depressive disorder.Semantic proximity Read ↗

Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: meta-analysis of data from genome-wide association studiesSemantic proximity Read ↗

CYP2C19 variation and citalopram response.Semantic proximity Read ↗

CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation.Semantic proximity Read ↗

Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19.Semantic proximity Read ↗

Effects of Cytochrome P450 (CYP) 2C19 Genotypes on Steady-State Plasma Concentrations of Escitalopram and its Desmethyl Metabolite in Japanese Patients With Depression.Semantic proximity Read ↗

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 updateSemantic proximity Read ↗

Combined effect of CYP2C19 and CYP2D6 genotypes on escitalopram serum concentration and its metabolic ratio in a European patient population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.